Cardio Intelligence Series B Second Close

Health Care · Japan · Undisclosed

Orthomos Investment underwrote the Series B second-close third-party allotment for Cardio Intelligence, a Tokyo-based AI ECG-analysis healthtech company, announced March 9, 2026. The round followed a November 2025 Series B first close led by Shin Nippon Biomedical Laboratories with Tokai Tokyo Investment and Iwagin Business Growth Capital. Amount undisclosed; proceeds are earmarked for product development of Cardio Intelligence's SmartRobin AI and SmartPAFin software-as-medical-device lines, team expansion, and overseas expansion.